Abstract
The French drug company Servier will buy Shire’s cancer-drug business for $2.4 billion. Shire’s marketed products for leukemia and pancreatic cancer represent less than 2% of the rare-disease drug company’s sales. Shire also has an experimental treatment for leukemia under review at the U.S. FDA. News of the sale comes about two weeks after Japan’s Takeda Pharmaceutical announced it was considering a bid to acquire Shire.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
